Dr. Kathryn Cunningham Hourdequin, MD

Dr. Hourdequin practices at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health.

Dr. Hourdequin's NPI, 1710978846, was assigned on October 28, 2005. Dr. Hourdequin graduated from Yale University School of Medicine in 2000. Dr. Hourdequin holds New Hampshire license 15797.

Dr. Hourdequin's primary practice is Dartmouth Hitchcock Medical Center, at 1 Medical Center Drive, Lebanon, NH 03756 in Grafton County. The practice phone is (603) 650-5000.

Dr. Hourdequin's primary practice is Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health. Dr. Hourdequin is also affiliated with Cheshire Medical Center. The medical group on file is Dartmouth Hitchcock Medical Center. Dmand AI also links Dr. Hourdequin to 3 more hospitals and 1 medical group, each named with a free account. Dr. Hourdequin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hourdequin practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hourdequin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hourdequin is licensed in New Hampshire.

CMS data shows 461 Medicare services from Dr. Hourdequin across 6 procedure codes in 2024, for 135 Medicare patients. Medicare paid $33,739 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 135 Medicare patients who saw Dr. Hourdequin in 2024. The largest group is 65 to 74, with 60 patients. 70% of them have high blood pressure, and 53% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hourdequin's median patient age at 68, with 51% women.

In 2024, Dr. Hourdequin wrote 495 Medicare Part D claims for 82 patients. 70% of them were for generic drugs. CMS names the drug for 308 of them, across 14 drugs with 11 or more claims each, at $157,945 in total drug cost. In 2023, CMS named 264 claims across 15 drugs.

Dr. Hourdequin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hourdequin as offering telehealth.

Dmand AI links 4 papers to Dr. Hourdequin, published from 2013 to 2025. Dr. Hourdequin's most frequent co-authors are Gregory Harold Ripple, MD, Kerrington David Smith, MD and Bassem Isaac Zaki, MD.

Dmand AI links Dr. Hourdequin to 10 clinical trials, 5 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Carcinoma, Neuroendocrine. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 2 general payments to Dr. Hourdequin from 2 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. Taiho Oncology, Inc. paid the most, $148.

Dr. Hourdequin graduated from Yale University School of Medicine in 2000.